Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Howell

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Anesthesia and Analgesia|January 12, 2024
Public Health Informatics and the Perioperative Physician: Looking to the FutureSeshadri C Mudumbai, Rodney A Gabriel, Stephen Howell, et al.
Epilepsia|May 16, 2008
Severe autosomal dominant nocturnal frontal lobe epilepsy associated with psychiatric disorders and intellectual disabilityChristopher P Derry, Sarah E Heron, Fiona Phillips, et al.
Plos One|October 3, 2012
Molecular evidence for gender differences in the migratory behaviour of a small seabirdRenata J Medeiros, R Andrew King, William O C Symondson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 21, 2020
Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapiesRonan N McGinty, Adam Handel, Teresa Moloney, et al.
Journal of Translational Medicine|January 31, 2014
Tumor infiltrating B-cells are increased in prostate cancer tissueJason R Woo, Michael A Liss, Michelle T Muldong, et al.
Journal of Translational Medicine|May 30, 2020
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancerStephen T Ryan, Jing Zhang, Danielle N Burner, et al.
Lab on a Chip|March 29, 2019
A high-speed, high-performance, microfabricated comprehensive two-dimensional gas chromatographJoshua J Whiting, Edward Myers, Ronald P Manginell, et al.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Health Technology Assessment (Winchester, England)|December 21, 2021
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTsAnthony G Marson, Girvan Burnside, Richard Appleton, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Anesthesia and Analgesia|January 12, 2024
Public Health Informatics and the Perioperative Physician: Looking to the FutureSeshadri C Mudumbai, Rodney A Gabriel, Stephen Howell, et al.
Epilepsia|May 16, 2008
Severe autosomal dominant nocturnal frontal lobe epilepsy associated with psychiatric disorders and intellectual disabilityChristopher P Derry, Sarah E Heron, Fiona Phillips, et al.
Plos One|October 3, 2012
Molecular evidence for gender differences in the migratory behaviour of a small seabirdRenata J Medeiros, R Andrew King, William O C Symondson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 21, 2020
Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapiesRonan N McGinty, Adam Handel, Teresa Moloney, et al.
Journal of Translational Medicine|January 31, 2014
Tumor infiltrating B-cells are increased in prostate cancer tissueJason R Woo, Michael A Liss, Michelle T Muldong, et al.
Journal of Translational Medicine|May 30, 2020
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancerStephen T Ryan, Jing Zhang, Danielle N Burner, et al.
Lab on a Chip|March 29, 2019
A high-speed, high-performance, microfabricated comprehensive two-dimensional gas chromatographJoshua J Whiting, Edward Myers, Ronald P Manginell, et al.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Health Technology Assessment (Winchester, England)|December 21, 2021
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTsAnthony G Marson, Girvan Burnside, Richard Appleton, et al.
Pageof 5